Pyxis Oncology Q2 EPS Forecast Decreased by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Research analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for shares of Pyxis Oncology in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.36) for the quarter, down from their prior estimate of ($0.31). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($0.60) EPS.

Separately, Royal Bank of Canada reiterated an “outperform” rating and set a $8.00 price target on shares of Pyxis Oncology in a research note on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Pyxis Oncology Stock Performance

Shares of Pyxis Oncology stock opened at $1.21 on Wednesday. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.39. The company has a market cap of $74.96 million, a P/E ratio of -1.17 and a beta of 1.15. The firm has a fifty day moving average of $1.06 and a two-hundred day moving average of $1.60.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.06).

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Barclays PLC boosted its position in shares of Pyxis Oncology by 275.0% during the 3rd quarter. Barclays PLC now owns 64,089 shares of the company’s stock worth $235,000 after purchasing an additional 46,997 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in Pyxis Oncology by 61.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock worth $41,000 after buying an additional 10,000 shares in the last quarter. American Century Companies Inc. grew its position in Pyxis Oncology by 88.1% during the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company’s stock worth $468,000 after buying an additional 140,498 shares during the period. Sei Investments Co. purchased a new position in Pyxis Oncology in the fourth quarter valued at about $95,000. Finally, Aristides Capital LLC purchased a new position in Pyxis Oncology in the fourth quarter valued at about $193,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.